摘要
文章介绍弥漫大B细胞淋巴瘤目前的治疗方法和病理生理学特点,特别是核转录因子-κB复合物及其靶基因Gadd45β如何在抑制JNK介导的凋亡通路中发挥作用,这与目前对DTP3的研究有关。DTP3是一种新型的Gadd45β靶向药物,其对多发性骨髓瘤具有显著的疗效和特殊的安全性。
This article introduces the current treatment methods and pathophysiology characteristics of diffuse large B-cell lymphoma, especially how nuclear factor-κB complex and its target gene Gadd45β play a role in inhibiting JNK-mediated apoptosis pathways. This will be relevant to current studies on DTP3, a novel Gadd45β-targeted agent that has shown significant efficacy and exceptional safety in multiple myeloma.
作者
田珂凡
Tian Ke-fan(Guangdong Pharmaceutical University,Guangzhou 510006,Guangdong Province,China)
出处
《中国社区医师》
2022年第10期7-9,共3页
Chinese Community Doctors
